A Phase 1 interventional study of Delgocitinib in Chronic Hand Eczema, sponsored by LEO Pharma. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by LEO Pharma · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Eczema by LEO Pharma — 1 open to participants now, 1 under way, none of them phase 3. Eczema · LEO Pharma.
Among the 13 studies in Eczema by LEO Pharma, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2022, is one of 2 in phase 1, and was the 11th registered.
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
Browse Eczema studies →1 of the 13 studies in Eczema by LEO Pharma is open now, in 1 country. Recruiting first, the newest first:
LEO Pharma · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 91 across 403 interventional studies indexed under Eczema.
Median enrollment 178 across the 12 interventional studies, 1,000 across the 1 observational. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
LEO Pharma is the lead sponsor of 225 studies on the registry; 5 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 24 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Eczema by LEO Pharma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to test how much delgocitinib enters the body over a given time period after application of delgocitinib cream in patients with moderate to severe hand eczema.
Delgocitinib is a cream that suppresses specific processes in the body's response to diseases like CHE, such as inflammation. Everyone in the trial will use delgocitinib cream.
The trial will last up to 7 weeks and there will be 6 visits and a phone call. There will be a screening period of up to 4 weeks, a treatment period (with blood sampling) of 11 days and a safety follow-up phone call 11 days after the last visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twice-daily topical application for 8 days
Drug: Delgocitinib
Cream for topical application 20 mg/g
Area under the concentration-time curve 0-12 hours post dose at Day 1 and Day 8 (AUC0-12).
Time frame: 0-12 hours post dose at Day 1 and Day 8
Maximum observed concentration (Cmax) at Day 1 and at Day 8 (0-12 hours post-dose).
Time frame: Day 1 and at Day 8 (0-12 hours post-dose)
Time to reach maximum observed concentration (tmax) at Day 1 and Day 8 (0-12 hours post-dose).
Time frame: Day 1 and Day 8 (0-12 hours post-dose).
Terminal elimination half-life (t1/2) at Day 8.
Time frame: Day 8.
Number of treatment-emergent adverse events (AEs) from baseline to Day 22 per subject.
Time frame: Baseline to Day 22
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Nov 2022, 2 months.
Of 16 phase 1 interventional studies under Eczema, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Delgocitinib